Role of epidermal growth factor receptor in breast cancer.
Role of epidermal growth factor receptor in breast cancer.
复制标题
DOI：
10.1007/s10549-012-2289-9
复制
发表时间：
2012-11
影响因子：
3.8
通讯作者：
Ueno, Naoto T.
中科院分区：
文献类型：
--
作者：
Masuda, Hiroko;Zhang, Dongwei;Bartholomeusz, Chandra;Doihara, Hiroyoshi;Hortobagyi, Gabriel N.;Ueno, Naoto T.
几十年来，分子肿瘤学的研究已经带来了有希望的新疗法，这些疗法旨在针对促进肿瘤生长和生存的特定分子。表皮生长因子受体(EGFR)是这些新型抗肿瘤药物最早发现的重要靶点之一。大约一半的三阴性乳腺癌(TNBC)和炎性乳腺癌(IBC)过表达EGFR。因此，用于乳腺癌治疗的EGFR抑制剂已经在几项研究中进行了评估。然而，到目前为止，结果令人失望。这些意想不到的结果的原因之一是缺乏生物标志物来预测哪些患者最有可能对EGFR抑制剂产生反应。最近的研究表明，EGFR及其下游通路调控上皮-间充质转化、迁移和肿瘤侵袭，EGFR高表达是IBC预后不良的独立预测因素。此外，最近的研究表明，靶向EGFR通过重新连接TNBC中的凋亡信号网络来增强TNBC细胞的化疗敏感性。这些研究表明，EGFR靶向治疗可能在TNBC和IBC中发挥有希望的作用。需要进一步研究EGFR在TNBC和IBC中的作用，以更好地了解使用EGFR靶向治疗的最佳方式--例如，作为化学增敏剂或防止转移--治疗这些侵袭性疾病。
Decades of research in molecular oncology have brought about promising new therapies that are designed to target specific molecules that promote tumor growth and survival. The epidermal growth factor receptor (EGFR) is one of the first identified important targets of these novel antitumor agents. Approximately half of cases of triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC) overexpress EGFR. Thus, EGFR inhibitors for treatment of breast cancer have been evaluated in several studies. However, results so far have been disappointing. One of the reasons for these unexpected results is the lack of biomarkers for predicting which patients are most likely to respond to EGFR inhibitors. Recent studies have shown that EGFR and its downstream pathway regulate epithelial-mesenchymal transition, migration, and tumor invasion and that high EGFR expression is an independent predictor of poor prognosis in IBC. Further, recent studies have shown that targeting EGFR enhances the chemosensitivity of TNBC cells by rewiring apoptotic signaling networks in TNBC. These studies indicate that EGFR-targeted therapy might have a promising role in TNBC and IBC. Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy—e.g., as a chemosensitizer or to prevent metastases—to treat these aggressive diseases.
登录
查看更多内容
影响因子：
50.5
作者：
Corkery, B.;Crown, J.;O'Donovan, N.
通讯作者：
O'Donovan, N.
影响因子：
11.5
作者：
Arteaga, Carlos L.;O'Neill, Anne;Davidson, Nancy E.
通讯作者：
Davidson, Nancy E.
影响因子：
11.5
作者：
Calvo, E;Tolcher, AW;Rowinsky, EK
通讯作者：
Rowinsky, EK
影响因子：
5.6
作者：
Baillo, Andrea;Giroux, Craig;Ethier, Stephen P.
通讯作者：
Ethier, Stephen P.
影响因子：
45.3
作者：
Erlichman, Charles;Hidalgo, Manuel;Rowinsky, Eric K.
通讯作者：
Rowinsky, Eric K.